Literature DB >> 26951445

Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables.

Semra Paydas1, Arbil Acikalin2, Melek Ergin2, Hikmet Celik3, Basak Yavuz3, Kahraman Tanriverdi4.   

Abstract

miRNAs are small RNAs and control the expression of protein-encoding genes. The aim of this study was to determine the association between miRNA profile and clinical variables including age, stage, B symptom, histopathologic subtype, response to treatment, disease-free survival (DFS) and overall survival (OS) in classical Hodgkin lymphoma (cHL). A total of 377 miRNAs were studied by qPCR in 32 cases with cHL, and results were compared with 60 samples taken from cases with reactive lymphadenopathy. Biogazelle qbasePLUS 2.0 software was used to analyze the results. miR-582-3p, miR-525-3p, miR-448, miR-512-3p, miR-642a-5p, miR-876-5p, miR-532-3p, miR-654-5p, miR-128, miR-145-5p, miR-15b-5p, miR-328 and miR-660-5p were found to be decreased in cHL compared with controls. In contrast, miR-34a-5p (2.626-fold), miR-146a-5p (4.32-fold), miR-93-5p (2.347-fold), miR-20a-5p (4.930-fold), miR-339-3p (4.948-fold), miR-324-3p (4.98-fold), miR-372 (7.038-fold), miR-127-3p (8.234-fold), miR-155-5p (4.947-fold), miR-320a (17.502-fold) and miR-370 (21.479-fold) (p < 0.05) were found to be increased in cHL. There was no difference in miRNA profile according to the age, sex, stage, response to treatment, DFS and OS. However, miR-889 was found to be increased in patients with B symptom and miR-127-3p was found to be increased in nodular sclerosing subtype. Some miRNAs increase and some decrease in cHL. However, there was no clinical association between clinical variables and with the majority of the miRNA profile studied in this study. miR-889 and miR-127-3p were related to B symptom and nodular sclerosis subtype, respectively. We need more studies evaluating miRNA profile and clinical outcome in Hodgkin Lymphoma.

Entities:  

Keywords:  B symptom; Clinicopathological correlation; Hodgkin lymphoma; Prognosis; Subtype; Survival; miRNA; qPCR

Mesh:

Substances:

Year:  2016        PMID: 26951445     DOI: 10.1007/s12032-016-0749-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  15 in total

1.  Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.

Authors:  Stephen M Ansell
Journal:  Am J Hematol       Date:  2014-07       Impact factor: 10.047

2.  BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.

Authors:  Joost Kluiver; Sibrand Poppema; Debora de Jong; Tjasso Blokzijl; Geert Harms; Susan Jacobs; Bart-Jan Kroesen; Anke van den Berg
Journal:  J Pathol       Date:  2005-10       Impact factor: 7.996

Review 3.  Systemic mirnas as potential biomarkers for malignancy.

Authors:  N A Healy; H M Heneghan; N Miller; C K Osborne; R Schiff; M J Kerin
Journal:  Int J Cancer       Date:  2012-07-30       Impact factor: 7.396

Review 4.  MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.

Authors:  William C S Cho
Journal:  Int J Biochem Cell Biol       Date:  2009-12-22       Impact factor: 5.085

5.  Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.

Authors:  Alfons Navarro; Tania Diaz; Antonio Martinez; Anna Gaya; Aina Pons; Bernat Gel; Carles Codony; Gerardo Ferrer; Carmen Martinez; Emili Montserrat; Mariano Monzo
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

6.  Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs.

Authors:  Pieter Van Vlierberghe; An De Weer; Pieter Mestdagh; Tom Feys; Katleen De Preter; Pascale De Paepe; Kathleen Lambein; Jo Vandesompele; Nadine Van Roy; Bruno Verhasselt; Bruce Poppe; Frank Speleman
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

7.  MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.

Authors:  Kui Nie; Mario Gomez; Pablo Landgraf; Jose-Francisco Garcia; Yifang Liu; Leonard H C Tan; Amy Chadburn; Thomas Tuschl; Daniel M Knowles; Wayne Tam
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

Review 8.  MicroRNAs and lymphomagenesis: a functional review.

Authors:  Charles H Lawrie
Journal:  Br J Haematol       Date:  2012-12-04       Impact factor: 6.998

Review 9.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

10.  MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma.

Authors:  Beatriz Sánchez-Espiridión; Ana M Martín-Moreno; Carlos Montalbán; Vianihuini Figueroa; Francisco Vega; Anas Younes; L Jeffrey Medeiros; Francisco J Alvés; Miguel Canales; Mónica Estévez; Javier Menarguez; Pilar Sabín; María C Ruiz-Marcellán; Andrés Lopez; Pedro Sánchez-Godoy; Fernando Burgos; Carlos Santonja; José L López; Miguel A Piris; Juan F Garcia
Journal:  Br J Haematol       Date:  2013-06-01       Impact factor: 6.998

View more
  32 in total

1.  MiR-876-5p suppresses epithelial-mesenchymal transition of lung cancer by directly down-regulating bone morphogenetic protein 4.

Authors:  Liang Bao; Lei Lv; Jinping Feng; Yuyu Chen; Xinhua Wang; Shuguang Han; Hongqing Zhao
Journal:  J Biosci       Date:  2017-12       Impact factor: 1.826

2.  MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma.

Authors:  Shuna Yao; Yanyan Liu; Zhihua Yao; Yan Zhao; Haiying Wang; Yuanlin Xu; Jiuyang Zhang; Jing Li; Shujun Yang
Journal:  Oncol Lett       Date:  2018-06-22       Impact factor: 2.967

3.  microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells.

Authors:  Haitao Xie; Qiugui Zhang; Hui Zhou; Jun Zhou; Ji Zhang; Yan Jiang; Jinghong Wang; Xianglin Meng; Leping Zeng; Xiaoxin Jiang
Journal:  Cytotechnology       Date:  2017-05-26       Impact factor: 2.058

4.  MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

Authors:  Blanca Majem; Alfonso Parrilla; Carlos Jiménez; Leticia Suárez-Cabrera; Marta Barber; Andrea Marín; Josep Castellví; Gabriel Tamayo; Gema Moreno-Bueno; Jordi Ponce; Xavier Matias-Guiu; Francesc Alameda; Ignacio Romero; José Luis Sánchez; Asunción Pérez-Benavente; Sebastián Moran; Manel Esteller; Jaume Reventós; Marina Rigau; Antonio Gil-Moreno; Miguel F Segura; Anna Santamaría
Journal:  Oncogene       Date:  2019-07-05       Impact factor: 9.867

5.  MiR-106a-5p promotes 5-FU resistance and the metastasis of colorectal cancer by targeting TGFβR2.

Authors:  Jian Liu; Yanqin Huang; Hongqian Wang; Denghai Wu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

6.  Long Non-Coding RNA NEAT1 Promoted Hepatocellular Carcinoma Cell Proliferation and Reduced Apoptosis Through the Regulation of Let-7b-IGF-1R Axis.

Authors:  Qin Liu; Hexian Shi; Jianbo Yang; Ning Jiang
Journal:  Onco Targets Ther       Date:  2019-11-29       Impact factor: 4.147

Review 7.  New developments in the pathology of malignant lymphoma. A review of the literature published from January-April 2016.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2016-06-13       Impact factor: 0.196

Review 8.  Non-Coding RNAs in Hodgkin Lymphoma.

Authors:  Anna Cordeiro; Mariano Monzó; Alfons Navarro
Journal:  Int J Mol Sci       Date:  2017-05-29       Impact factor: 5.923

9.  Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.

Authors:  Liang-Liang Li; Li-Li Qu; Han-Jiang Fu; Xiao-Fei Zheng; Chuan-Hao Tang; Xiao-Yan Li; Jian Chen; Wei-Xia Wang; Shao-Xing Yang; Lin Wang; Guan-Hua Zhao; Pan-Pan Lv; Min Zhang; Yang-Yang Lei; Hai-Feng Qin; Hong Wang; Hong-Jun Gao; Xiao-Qing Liu
Journal:  Oncotarget       Date:  2017-07-11

Review 10.  microRNAs Make the Call in Cancer Personalized Medicine.

Authors:  Simone Detassis; Margherita Grasso; Valerio Del Vescovo; Michela A Denti
Journal:  Front Cell Dev Biol       Date:  2017-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.